Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic

Yi Wang1 · Nantasit Luangasanatip2 · Wirichada Pan-ngum2 · Wanrudee Isaranuwatchai3 · Juthamas Prawjaeng3 · Sompob Saralamba2 · Christopher Painter2,3 · Jamaica Roanne Briones1 · Yot Teerawattananon1,3

Received: 16 October 2021 / Accepted: 26 July 2022 / Published online: 11 August 2022 © The Author(s) 2022

Abstract

Objective This study aimed to assess the cost-effectiveness of COVID-19 vaccines, preferred COVID-19 vaccine profiles, and the preferred vaccination strategies in Thailand.

Methods An age-structured transmission dynamic model was developed based on key local data to evaluate economic consequences, including cost and health outcome in terms of life-years (LYs) saved. We considered COVID-19 vaccines with different profiles and different vaccination strategies such as vaccinating elderly age groups (over 65s) or high-incidence groups, i.e. adults between 20 and 39 years old who have contributed to more than 60% of total COVID-19 cases in the country thus far. Analyses employed a societal perspective in a 1-year time horizon using a cost-effectiveness threshold of 160,000 THB per LY saved. Deterministic and probabilistic sensitivity analyses were performed to identify and characterize uncertainty in the model.

Results COVID-19 vaccines that block infection combined with social distancing were cost-saving regardless of the target population compared to social distancing alone (with no vaccination). For vaccines that block infection, the preferred (cost-effective) strategy was to vaccinate the high incidence group. Meanwhile, COVID-19 vaccines that reduces severity (including hospitalization and mortality) were cost-effective when the elderly were vaccinated, while vaccinating the high-incidence group was not cost-effective with this vaccine type. Regardless of vaccine type, higher vaccination coverage, higher efficacy, and longer protection duration were always preferred. More so, vaccination with social distancing measures was always preferred to strategies without social distancing. Quarantine-related costs were a major cost component affecting the cost-effectiveness of COVID-19 vaccines.

Conclusion COVID-19 vaccines are good value for money even in a relatively low-incidence and low-mortality setting such as Thailand, if the appropriate groups are vaccinated. The preferred vaccination strategies depend on the type of vaccine efficacy. Social distancing measures should accompany a vaccination strategy.

Keywords SARS-CoV-2 · COVID-19 · Vaccine · Vaccination · Cost-effectiveness · Economic evaluation · Thailand

Abbreviations

NPIs Non-pharmacological interventions
CoMo consortium The COVID-19 International Modelling Consortium
SEIR Susceptible–Exposed–Infectious–Recovered
TPP Target product profile
SD Social distancing
Lys Life-years
NHSO National Health Security Office
RT-PCR Real-time reverse transcription polymerase chain reaction
PPE Personal protective equipment

* Wanrudee Isaranuwatchai
wanrudee.i@hitap.net

1 Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
2 Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
3 Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand
for the full cost of COVID-19 vaccines. They should be
and upper-middle-income countries, which will need to pay
gies. This type of analysis is very relevant to high-income
tive costs and consequences of different vaccination strate-
what is the economically justifiable price in negotiations
for a vaccine.

for example: (i) what are the most desirable COVID-19 vac-
cination strategy. Such questions governments face include,
and whom to vaccinate so that future large
coming approximately 80% of the population); (2) the Social
the Thai government needs to decide which
by a country with a relatively low local transmission and
more details on number of COVID-19 cases and deaths
during this time are shown in Supplementary Informa-
mortality (the situation for Thailand in January–May, 2020;
these interventions, the
incidence rate and mortality rate of COVID-19 remained
by the early implementation of these interventions, the
interventions were relaxed towards the end of June of 2020.
Due to the early implementation of these interventions,
low in Thailand in 2020. There was a surge in the number
mortality (the situation for Thailand in January–May, 2020;
more details on number of COVID-19 cases and deaths
during this time are shown in Supplementary Informa-
mortality (the situation for Thailand in January–May, 2020;
more details on number of COVID-19 cases and deaths
during this time are shown in Supplementary Informa-
tions. This type of analysis is very relevant to high-income
and upper-middle-income countries, which will need to pay
for the full cost of COVID-19 vaccines. They should be
well-prepared for short and long-term procurement plans,
including vaccine selection and pricing negotiations, to
ensure that the significant investment in a COVID-19 vac-
cine justifies its opportunity costs from displaced investment
in the health sector or across public programs.

This paper shares the methodological approach and
results from an economic evaluation conducted to inform
policy decisions regarding COVID-19 vaccination in
Thailand. Thailand implemented Universal Health Cov-
erage Scheme in 2002 [3]. Thailand’s healthcare system
includes both public and private sectors, where the public
health insurance schemes are offered through three differ-
ent schemes: (1) the Universal Coverage Scheme (cover-
ing approximately 80% of the population); (2) the Social
Security Scheme (13% of the population); and (3) the Civil
Servant Medical Benefit Scheme (7% of the population) [4].
Unlike traditional economic evaluations, which inform about
accepting or rejecting a vaccine, this Thai government com-
missoned study addresses different policy questions faced
by a country with a relatively low local transmission and
mortality (the situation for Thailand in January–May, 2020;
more details on number of COVID-19 cases and deaths
during this time are shown in Supplementary Informa-
mortality (the situation for Thailand in January–May, 2020;
more details on number of COVID-19 cases and deaths
during this time are shown in Supplementary Informa-
tions. This type of analysis is very relevant to high-income
and upper-middle-income countries, which will need to pay
for the full cost of COVID-19 vaccines. They should be

Introduction

The COVID-19 pandemic will not end until the global roll-
out of vaccines is fully realized and when people from all
corners of the world are directly or indirectly protected
against the virus. Although national health regulators around
the globe have authorized emergency use of COVID-19 vac-
cines at a very fast pace, having licensed vaccines is not
equivalent to achieve global control of COVID-19 [1]. The vac-
cines need to be produced at scale, priced affordably and
delivered strategically so that local outbreaks can be con-
trolled, and life can return to normal.

Currently, there are more than a hundred COVID-19
vaccine candidates in clinical studies, with 15 approved for
human use [2]. Approved vaccines differ substantially in
costs, cold-storage requirements, clinical efficacy, and safety
profile, and vaccines in development will likely differ fur-
ther. As such, country governments face decisions on choos-
ing the most appropriate vaccine(s) and will continue to do
so – given their country profiles, outbreak situation, and
vaccination strategy. Such questions governments face include,
for example: (i) what are the most desirable COVID-19 vac-
cine characteristics, e.g. alternative types of vaccine efficacy,
protection duration and price, for prevention and control
from an economic perspective; (ii) which subpopulation
groups – stratified by age, occupation, geographical location
or other characteristics – should be prioritized given limited
vaccine supplies; (iii) what is the best value for money
in terms of a combination of non-pharmaceutical interven-
tions (NPIs) and vaccines for controlling COVID-19; (iv)
what is the economically justifiable price in negotiations
for a vaccine.

Economic evaluation can be usefully employed to address
such above questions, by systematically comparing the rela-
tive costs and consequences of different vaccination strate-
gies. This type of analysis is very relevant to high-income
and upper-middle-income countries, which will need to pay
for the full cost of COVID-19 vaccines. They should be

| Abbreviation | Full Form |
|--------------|-----------|
| PUI          | Patients under investigation |
| MOPH         | Ministry of Public Health |
| AE           | Adverse event |
| DDC          | Department of Disease Control |
| THB          | Thai baht |
| ICERs        | Incremental cost-effectiveness ratios |
| NLEM         | National List of Essential Medicines |
| PSA          | Probabilistic sensitivity analysis |
| DSA          | Deterministic sensitivity analysis |
| NMB          | Net monetary benefit |
| VOI          | Value of information |
| EVPI         | Expected value of perfect information |
| AZD1222      | Oxford/AstraZeneca |
process). Therefore, vaccine prioritization was an important healthcare decision for the Thai government. This study further assists the Thai government in making transparent and fair recommendations on initially prioritized population groups for vaccination, and subsequent rounds of vaccination.

Methods

Transmission dynamic and economic model

An age-structured epidemiological model developed by the Covid-19 International Modelling Consortium (CoMo consortium) was adapted by Luangasanatip N et al. [7, 8] to estimate age-stratified incidence and deaths of COVID-19 infection under different scenarios of vaccine characteristics, vaccination strategy, and combination of NPIs. In brief, the transmission model was developed based on an SEIR (Susceptible-Exposed-Infectious-Recovered) structure. The I compartment of the transmission dynamic model was stratified by the severity of infection (no symptoms, mild symptoms, intensive care unit with a ventilator). Country-specific epidemiology, clinical, vaccine and NPI parameters were used in the model. Different conditions of hypothetical vaccine characteristics were considered based on the WHO target product profile (TPP), [9] including different target populations (high risk elderly aged ≥ 65 years or a high-incidence group aged 20–39 years), vaccinated population sizes (5 million, 9 million and 15 million people vaccinated (regardless of number of doses)), efficacy type (infection blocking and severity reduction which aim to reduce both hospitalization and mortality), level of efficacy (50, 70 and 90%), duration of protection (0.5 and 1 year), and social distancing (SD) implementation (with and without SD) were explored to estimate the impact of a COVID-19 vaccine on incidence and death. In the study setting (Thailand), there are approximately 12 million elderly (~18% of total population of approximately 66 million people) and those aged 15–59 years accounted for 64% of total population as of January 2022. More details on the transmission dynamic model are available in Supplementary Information 2. The outputs from the transmission dynamic model were fed into the economic model for evaluating economic consequences (cost and health outcomes or life-years, LYs, saved) of various vaccination strategies (based on target population, level of efficacy, and duration of protection) compared to no vaccination with social distancing. The study adopted a societal perspective using a one-year time horizon. The study did not require the approval of the independent ethics committee because it was based on a mathematical and economic model to simulate the cost and outcome and did not include human participants.

Model input parameters

Although Thailand has methodological guidelines for conducting economic evaluations of healthcare interventions, it was agreed that certain aspects of these guidelines were not appropriate for evaluations of COVID-19 vaccines during stakeholder engagement meetings. This issue was discussed further in a related methodological principles research article for the Thai and Singaporean economic evaluations of COVID-19 vaccination [10].

Cost variables

The cost analysis was done from a societal perspective. Cost parameters included direct medical costs, direct non-medical costs and indirect costs. Direct medical costs for COVID-19 infection treatment were retrieved from electronic individual records of the e-claim database of the National Health Security Office (NHSO) [11]. Due to limited data availability, the treatment cost for asymptomatic cases was assumed to be zero, on the basis that these cases would not be identified by the healthcare system and therefore would not be treated. Costs for contact tracing and testing included the cost of real-time reverse transcription polymerase chain reaction (RT-PCR), personal protective equipment (PPE) for technicians [12], and costs of tracing derived from literature [13]. The proportion of asymptomatic cases detected which were traced and tested was obtained from a systematic review and meta-analysis [14]. The number of patients under investigation (PUI) per confirmed case was derived from data from the Thai Ministry of Public Health (MOPH) and was pegged at 44.4 persons [15]. Costs for transmission prevention including face masks and disinfection agents were obtained from an e-commerce market, which has been a major supplier during the pandemic [16]. Costs for the vaccination program, including vaccine price (for two doses), supply chain, and logistic and hospital-based administration were based on publicly available data and existing literature from a flu vaccination program in Thailand, respectively [17, 18]. Costs of treating thromboembolic events, a serious adverse event (AE), were analyzed by identifying ICD-10 codes related to thromboembolic events [19] from an e-claim database of the NHSO in Thailand [20]. The incidence rate of thromboembolic events was obtained from existing evidence [19]. Direct non-medical costs related to quarantine costs were obtained from the Department of Disease Control (DDC) [21], including accommodation and meals for 14 days. Based on personal communication with DDC staff, we assumed 10 high-risk of infection PUI per confirmed case. Indirect costs from implementing non-pharmaceutical interventions (NPIs) including the impact...
of social distancing on the economy was estimated using gross domestic product [22], the stock market index [23], and other control variables to control for local and global COVID-19 cases, global economic status, and other government policies. Details of the time series analysis conducted can be found in the Supplementary Information 6 and a related methodological research article [24]. All cost parameters were converted to 2020 values using the consumer price index (CPI) [25] and presented in Thai baht (THB) where 1 USD = 35.8 THB (Table 1).

### Outcome estimates

Outcomes were measured in LY saved by using the age-stratified life loss, using the Thailand standard lifetable [26].

### Data analysis

The primary results of the analysis were incremental cost-effectiveness ratios (ICERs), in THB per LY saved. We used the ceiling threshold of 160,000 THB per LY saved in our analysis, as recommended by the Subcommittee for the

### Table 1 Parameter values

| Variable name | Variable Explanation | Mean  | SD    |
|---------------|----------------------|-------|-------|
| Cost_dmed_nsev_1 | Direct medical cost per patient for patient aged 4 and below with mild to moderate symptoms | 32,893 | 23,379 |
| Cost_dmed_nsev_2 | Direct medical cost per patient for patient aged 5 to 14 with mild to moderate symptoms | 29,139 | 20,254 |
| Cost_dmed_nsev_3 | Direct medical cost per patient for patient aged 15 to 39 with mild to moderate symptoms | 33,457 | 22,245 |
| Cost_dmed_nsev_4 | Direct medical cost per patient for patient 40 to 64 with mild to moderate symptoms | 37,514 | 23,661 |
| Cost_dmed_nsev_5 | Direct medical cost per patient for patient aged 65 and above with mild to moderate symptoms | 45,435 | 26,174 |
| Cost_dmed_sev_1 | Direct medical cost per patient for patient aged 4 and below with severe symptoms | 32,893 | 23,379 |
| Cost_dmed_sev_2 | Direct medical cost per patient for patient aged 5 to 14 with severe symptoms | 29,139 | 20,254 |
| Cost_dmed_sev_3 | Direct medical cost per patient for patient aged 15 to 39 with severe symptoms | 89,030 | 17,710 |
| Cost_dmed_sev_4 | Direct medical cost per patient for patient 40 to 64 with severe symptoms | 102,028 | 58,977 |
| Cost_dmed_sev_5 | Direct medical cost per patient for patient aged 65 and above with severe symptoms | 104,306 | 64,199 |
| Cost_dmed_dead | Direct medical cost per patient for patient that were infected with COVID-19 and died | 84,066 | 49,295 |
| Cost_dmed_asyp | Direct medical cost per patient for asymptomatic patient | 0 | NA |
| Cost_screen | Cost of COVID-19 screening | 1500 | 375 |
| Cost_vac_sup | Cost of vaccine supply management per dose | 19.59 | 4.8975 |
| Cost_vac_admin | Cost of vaccination administration at hospital per dose | 124.03 | 31.0075 |
| Cost_vac_aqui | Cost of vaccine acquisition per dose | 93 | 23.25 |
| Cost_mask_year | Cost of mask per person per year | 365 | 91.25 |
| Cost_hygiene_year | Cost of hygiene and sanitizing per person per year | 1200 | 300 |
| Cost_trace | Cost of contract tracing per person traced | 450 | 112.5 |
| Cost_quarantine | Cost of quarantine at designated facilities | 15,000 | 3750 |
| Cost_npi_sd | Cost of social distancing per year | 4.55E+10 | 2.28E+10 |
| Num_test_asyoversym | Number of asymptomatic cases tested per symptomatic case | 0.18 | 0.046 |
| Num_trace_perdetect | Number of people traced per detected case | 44.35 | 18 |
| Num_quarantine_perdetect | Number of people quarantined per detected case | 10 | 2.5 |
| Adverse_inci | Incidence of adverse event | 6E-6 | 1.5E-6 |
| Adverse_cost | Direct medical cost for patients with adverse event | 23,968 | 9093 |

All cost parameters were converted into 2020 Thai Baht

*a Analysis done by authors*
Development of the National List of Essential Medicines (NLEM).

Sensitivity analyses were performed to account for parameter uncertainty. A one-way deterministic sensitivity analysis (DSA) was conducted by varying one parameter at a time, while other parameters remain unchanged, to understand the impact of each individual parameter on the net monetary benefit (NMB) using a ceiling threshold of 160,000 THB per LY saved. We focused on the parameters listed in Table 1. We selected several scenarios examining the impact of different parameters on the incremental NMB comparing vaccination strategies with highest NMBs to no vaccine and comparing vaccination strategies with highest NMBs to alternative strategies. Social distancing was assumed to be implemented in all the scenarios in the sensitivity analysis. The results of the DSA were presented using tornado plots. A probabilistic sensitivity analysis (PSA) was conducted by sampling all model parameters from their statistical distributions. A value of information (VOI) analysis was conducted based on the results of the PSA.

Results

Cost-effectiveness analysis

Figure 1 shows the cost-effectiveness plane results when a vaccine with 70% efficacy and 1-year protection duration

![Cost-effectiveness plane](image)

**Notes:** Panel A considers a vaccine that blocks infection. Panel B considers a vaccine that reduce severity (including both hospitalisation and mortality). The dashed line in panel B represents the 160,000 Thai Baht per life-year. There is no strategy for 15M elderly as there is not enough elderly in the study setting.

**NV:** no vaccine

*Fig. 1* Cost-effectiveness plane – Different Vaccination Strategies for blocking infection and reducing severity
was considered. The comparator was no vaccine and without social distancing located at the origin. Panel A shows the results for a vaccine that blocks infection; panel B shows the results for a vaccine that reduces severity. If the vaccine blocks infection, under the scenario without social distancing, all vaccination strategies are cost-saving compared to no vaccination. Comparing vaccinating high-incidence group to vaccinating the elderly, e.g. triangle F versus triangle E, vaccinating high-incidence group saved more cost but fewer life years. Vaccinating high-incidence group was preferred over vaccinating elderly using the ceiling cost-effectiveness threshold of 160,000 THB per QALY (according to the Thai National HTA Guideline). Social distancing alone without vaccination, denoted by the dotted no vaccine, was more cost-saving compared to vaccination without social distancing when the number of vaccine was limited. When social distancing was implemented, all vaccination strategies were cost-saving compared to no vaccination, though high-incidence groups should be prioritized over general adults and the elderly. A figure using the strategy of no vaccine combining with social distancing as the comparator is presented in Supplementary Information 3 Fig S4 Panel A.

If the vaccine reduces severity, under the scenario without social distancing, vaccinating the elderly and the general adults were cost-effective. Vaccinating the elderly was preferred over vaccinating adults with lower incremental cost and more life years saved, e.g. triangle E versus triangle D. Social distancing alone provided better value for money compared to vaccination, i.e. dotted no vaccine versus triangles. When social distancing was implemented, only vaccinating the elderly represented good value for money. A figure using the strategy of no vaccine combining with social distancing as the comparator is presented in Supplementary Information 3 Fig S4 Panel B.

Breakdown costs for selected scenarios are presented in Table 2. While the results are not equivalent to budget impact analysis, they show the yearly cost or yearly budget required for each component if the Thailand government decides to fully subsidize the cost. Costs of quarantine, direct medical cost, and cost of contact tracing are lower with social distancing compared to without social distancing. Cost of quarantine and cost of contact tracing are lower with vaccines that blocks infection compared to vaccines that reduces severity.

Of the considered cost components, the leading cost was due to quarantine, which contributed approximately 30–70% of the total policy costs. Vaccine-related costs, including vaccine acquisition, vaccine supply chain, vaccine administration, and medical costs for vaccine-related adverse events, were relatively small compared to, for example, contact tracing and COVID-19 treatment costs.

Figure 2 shows the cost-effectiveness plane, where different vaccine profiles and vaccination strategies were considered. All scenarios considered included social distancing and a vaccinated population size of nine million. The figure also shows that the high-incidence group should be prioritized over the elderly if vaccines block infection, while the elderly should be prioritized if the vaccine only reduces severity. This figure also illustrates that vaccines with higher efficacy and longer protection duration are cost-effective compared to no vaccination with social distancing. COVID-19 vaccines with one-year protection duration and 20% lower efficacy represent better value for money than vaccines with 6 months protection duration and 20% higher efficacy, suggesting that duration of protection is an important vaccine characteristic. Results comparing different vaccine profiles and vaccination strategies without social distancing are presented in Supplementary Information 3 Fig S5. The results show the similar patterns as the results with social distancing.

Results exploring the impact of using different ceiling thresholds are presented in Supplementary Information 3 Fig S6. If vaccines block infection, all vaccination strategies yield positive NMBs at any ceiling threshold compared to no-vaccine scenario. Nevertheless, if vaccines reduce severity, offering vaccines to the elderly yields positive NMBs at ceiling thresholds higher than 20,000–100,000 THB per LY depending on levels of vaccine efficacy and protection duration.

**Sensitivity analysis**

Figure 3 shows the results of the one-way DSA under four different vaccine and target population scenarios. A vaccine with 70% efficacy and 1-year protection duration was considered. The x-axis represents the relative change in incremental NMB. A larger value indicates the parameter has higher impact on the incremental NMB. The cost-effectiveness results from the model are most sensitive to the vaccine efficacy parameter. Vaccine supply and administration costs did not have a large effect on the model results except when vaccines block infection. The model was also sensitive to costs related to quarantine for PUI when considering vaccines that block transmission.

Focusing on the strategies with social distancing, three strategies were compared in the PSA, including no vaccine, vaccinating elderly, and vaccinating high-incidence group. The PSA results, in Fig. 4 Panel A, show that the probability of vaccinating high-incidence groups with vaccines that block infection being the most cost-effective strategy was equal to 1 at all ceiling thresholds. For vaccines that reduce severity, in Fig. 4 Panel B, the probability of vaccinating high-incidence groups being the most cost-effective was equal to 0 at all ceiling thresholds. The probability of vaccinating elderly groups being the most cost-effective strategy was 1 for ceiling thresholds larger than 60,000 THB per LY.
Table 2  Breakdown cost (in Billion 2020 Thai Baht)

| Scenario                        | Dmed | Mask | Hygiene | Vaccine_aqui | Vaccine_supchain | Vaccine_admin | Adv.Event | CT     | Quarantine | SD | Total    |
|--------------------------------|------|------|---------|--------------|------------------|---------------|-----------|--------|------------|----|----------|
| Baseline_w_sd_40_rv1           | 107.02 | 7.65 | 25.15   | 0            | 0                | 0             | 51.16    | 384.48 | 45.51      | 620.98 |
| Vac_Eff1_5M_AgeEld_70_sd40_rv1 | 104.65 | 7.65 | 25.15   | 0.93         | 0.20             | 1.24          | 0.0007   | 50.25  | 377.67     | 45.51 | 613.26   |
| Vac_Eff1_5M_AgeHig_70_sd40_rv1 | 87.60  | 7.65 | 25.15   | 0.93         | 0.20             | 1.24          | 0.0007   | 41.93  | 315.11     | 45.51 | 525.32   |
| Vac_Eff1_09M_AgeEld_70_sd40_rv1| 102.89 | 7.65 | 25.15   | 1.67         | 0.35             | 2.23          | 0.0013   | 49.57  | 372.59     | 45.51 | 607.62   |
| Vac_Eff1_09M_AgeHig_70_sd40_rv1| 65.64  | 7.65 | 25.16   | 1.67         | 0.35             | 2.23          | 0.0013   | 31.46  | 236.44     | 45.51 | 416.12   |
| Vac_Eff1_15M_AgeHig_70_sd40_rv1| 26.70  | 7.65 | 25.16   | 2.79         | 0.59             | 3.72          | 0.0022   | 12.83  | 96.41      | 45.51 | 221.36   |
| Vac_Eff3_5M_AgeEld_70_sd40_rv1 | 106.84 | 7.65 | 25.15   | 0.93         | 0.20             | 1.24          | 0.0007   | 51.17  | 384.57     | 45.51 | 623.26   |
| Vac_Eff3_5M_AgeHig_70_sd40_rv1 | 107.57 | 7.65 | 25.15   | 0.93         | 0.20             | 1.24          | 0.0007   | 51.54  | 387.37     | 45.51 | 627.16   |
| Vac_Eff3_09M_AgeHig_70_sd40_rv1| 106.70 | 7.65 | 25.15   | 1.67         | 0.35             | 2.23          | 0.0013   | 51.18  | 384.64     | 45.51 | 625.09   |
| Vac_Eff3_09M_AgeEld_70_sd40_rv1| 108.00 | 7.65 | 25.15   | 1.67         | 0.35             | 2.23          | 0.0013   | 51.84  | 389.65     | 45.51 | 632.07   |
| Vac_Eff3_15M_AgeHig_70_sd40_rv1| 108.63 | 7.65 | 25.15   | 2.79         | 0.59             | 3.72          | 0.0022   | 52.29  | 393.05     | 45.51 | 639.39   |
| Baseline_w_sd_00_rv1_full      | 151.19 | 7.65 | 25.15   | 0            | 0                | 0             | 72.35    | 543.79 | 0.00       | 800.13 |
| Vac_Eff1_5M_AgeEld_70_sd0_rv1  | 147.28 | 7.65 | 25.15   | 0.93         | 0.20             | 1.24          | 0.0007   | 70.89  | 532.81     | 0.00 | 786.14   |
| Vac_Eff1_5M_AgeHig_70_sd0_rv1  | 137.90 | 7.65 | 25.15   | 0.93         | 0.20             | 1.24          | 0.0007   | 66.08  | 496.68     | 0.00 | 735.83   |
| Vac_Eff1_09M_AgeHig_70_sd0_rv1 | 144.39 | 7.65 | 25.15   | 1.67         | 0.35             | 2.23          | 0.0013   | 69.81  | 524.71     | 0.00 | 775.97   |
| Vac_Eff1_09M_AgeEld_70_sd0_rv1 | 127.64 | 7.65 | 25.15   | 1.67         | 0.35             | 2.23          | 0.0013   | 61.24  | 460.27     | 0.00 | 686.22   |
| Vac_Eff1_15M_AgeHig_70_sd0_rv1 | 111.49 | 7.65 | 25.15   | 2.79         | 0.59             | 3.72          | 0.0022   | 53.60  | 402.82     | 0.00 | 607.81   |
| Vac_Eff3_5M_AgeEld_70_sd0_rv1  | 150.70 | 7.65 | 25.15   | 0.93         | 0.20             | 1.24          | 0.0007   | 72.30  | 543.43     | 0.00 | 801.61   |
| Vac_Eff3_5M_AgeHig_70_sd0_rv1  | 151.75 | 7.65 | 25.15   | 0.93         | 0.20             | 1.24          | 0.0007   | 72.81  | 547.25     | 0.00 | 806.98   |
| Vac_Eff3_09M_AgeEld_70_sd0_rv1 | 150.33 | 7.65 | 25.15   | 1.67         | 0.35             | 2.23          | 0.0013   | 72.27  | 543.14     | 0.00 | 802.80   |
| Vac_Eff3_09M_AgeHig_70_sd0_rv1 | 152.22 | 7.65 | 25.15   | 1.67         | 0.35             | 2.23          | 0.0013   | 73.19  | 550.08     | 0.00 | 812.54   |
| Vac_Eff3_15M_AgeAdu_70_sd0_rv1 | 152.28 | 7.65 | 25.15   | 2.79         | 0.59             | 3.72          | 0.0022   | 73.41  | 551.73     | 0.00 | 817.33   |

This table shows the breakdown cost for each component. All cost were converted into 2020 Thai Baht

- **Dmed** direct medical cost
- **Vaccine_aqui** cost of vaccine acquisition
- **Vaccine_supchain** cost of vaccine supply chain
- **Vaccine_admin** cost of vaccine administration
- **Adv.Event** direct medical cost due to vaccine-related adverse event
- **CT** contract tracing
- **Quarantine** social distancing
- **Scenario start with Eff** vaccine efficacy type + number of people being vaccinated + population group to vaccinate + vaccine efficacy + with/without social distancing + protection duration

Vaccine efficacy type:  
- **Eff1** infection blocking
- **Eff3** severity reduction

Number of people being vaccinated:  
- 5 M 5 million
- 09 M 9 million
- 15 M 15 million

Population group to vaccinate:  
- **AgeEld** elderly group
- **AgeHig** high-incidence group

Vaccine efficacy: 70 – 70%

With/without social distancing:  
- **sd40** with social distancing
- **sd0** without social distancing

Protection duration: **rv1** 1 year
Hence, at a ceiling threshold of 160,000 THB per LY, the uncertainties in the preferred policy mainly arose from the type of vaccine efficacy considered.

As the actual profile of the vaccine, e.g. vaccine type, efficacy, protection duration, were unknown to the policy-makers at the point when they need to make decisions, we explored the expected incremental NMB of vaccinating high-incidence groups and vaccinating elderly groups with vaccines with different probability in blocking infection \( (1-p) \) and probability of reductions in severity \( (1-p) \) at a fixed level of overall efficacy. We assumed that the vaccine will either block infection for the vaccinated population or reduce severity for the vaccinated population. The expected incremental NMB was calculated as a linear combination of the incremental NMB of the scenario with the vaccine blocking infection and incremental NMB of the scenario with the vaccine reducing severity. Specifically, as shown in Fig. 5, we considered four scenarios with combinations of different overall vaccine efficacy and protection duration. The results inform that only an approximate 10–20% probability of blocking infection is enough to justify prioritizing high-incidence groups over elderly groups for COVID-19 vaccination in Thailand.
Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting...

**VOI analysis**

While an approximate 10–20% probability of blocking infection is enough to justify prioritizing high-incidence groups over elderly groups, there was no preliminary information available about the probability of vaccines blocking infection. Hence, we examined the population level expected value of perfect information (EVPI) by considering a range of probabilities that vaccines can block infection using a ceiling threshold of 160,000 THB per LY, as shown in Fig. 6. If the prior belief that the probability of the vaccine blocking infection is high enough, e.g. greater than 0.4, the EVPI, or the benefit of doing additional research to reduce the uncertainty in parameters, was close to 0. From this point onward, it is preferred to vaccinate high-incidence groups without requiring additional research to reduce parameter uncertainties. The peaks of EVPI were around 10–20%. This finding supported the results from Fig. 5 where the expected benefits are similar between vaccinating high-incidence group and elderly group. Under these scenarios, additional research can be justified to reduce the uncertainties in parameters.

**Discussion**

This study is the first economic evaluation of COVID-19 vaccines to inform policy decisions in an upper middle-income country with relatively low incidence and low mortality. From a societal perspective, if vaccines block infection, then vaccines are cost-saving for all population groups compared to no vaccination. If vaccines would only reduce severity, then vaccinating elderly groups is the preferred strategy. Although these findings indicate that cost-effectiveness of vaccination strategies depends on vaccine type; all vaccine efficacy trials, except AZD1222 (Oxford/AstraZeneca) trials [27], were not designed to address the key question of whether vaccines can reduce transmission [28]. However, observational studies conducted in Israel [29], England [30], and the United States [31] demonstrated relatively high vaccine effectiveness against SARS-CoV-2 B.1.1.7 or Alpha variant transmission (approximately 50–70%) in real-world situations. These empirical studies provide reassurance that, at the very least, mRNA and AstraZeneca COVID-19 vaccines offer dual benefits in terms of protecting symptomatic
and severe cases as well as preventing infections after getting the recommended doses of the vaccines. Applying this evidence to our study supports that vaccines can provide better value for money, meaning that vaccinating high-incidence groups is likely to be the preferred strategy in the Thai setting. With new COVID-19 variants keeping emerging over time, protection of COVID-19 vaccine is also expected to change [32, 33]. A contingent vaccination plan, considering the vaccine efficacy type, efficacy level, and protection duration in response to the changing epidemiological conditions, is important for all governments to adjust vaccination strategy and priority timely.

This local study applied a framework for "collaborative modelling for effective policy implementation and evaluation" through iterative stakeholder participation and discussion in order to enhance trust, accountability, and public ownership to decisions [34]. Series of public and stakeholder consultation meetings were conducted throughout the study. Results of this study were deliberated in the public media [35, 36] and the Vaccine Management Subcommittee including the Vaccine Research Working Group under the Subcommittee, a part of the Thai Ministry of Public Health [37]. The findings were used to guide vaccination strategies in Thailand where high-incidence populations were one of the priority groups, especially in areas with active local transmission. As of June 2, 2021, 3.7 million people (about 4% of the total Thai population) had received at least one dose of either AstraZeneca or CoronaVac vaccines. Of these, about 55% were health professionals or frontline civil servants, 35% were from high-incidence groups and 10% were elderly or people with underlying health conditions. Before the arrival of delta and omicron variants, this vaccination

Notes: Panel A: Vaccine blocks infection; Panel B: Vaccine reduces severity. Three strategies were compared: no vaccine, vaccinating elderly group, vaccinating high-incidence group.

Fig. 4 Probabilistic Sensitivity Analysis
policy may be more appropriate for Thailand as the country had low case fatality (0.67%) compared to other countries, especially in Europe and America with case fatality ranging between 1 and 12% [38]. In addition, many resource-rich countries anticipate relaxing social distancing (or other NPIs) upon vaccination roll-out since they can procure large supplies of vaccines, meaning that they can expect to achieve high levels of vaccine coverage. Given the limited vaccine supply, our study suggests social distancing should remain a vital part of COVID-19 response measures in Thailand. Table 2 illustrates the breakeven cost of social distancing that makes social distancing policy a cost-effective option, which estimated to be about 1% of GDP depending on the vaccination strategy.

Our results are in line with the previous findings in the United Kingdom (UK) [39], the United States (US) [40] and Turkey [41] that COVID-19 vaccines are either cost-saving or represent good value for money in high-incidence settings. Nevertheless, none of the previously mentioned studies consider restricted vaccine supplies which is a major issue faced by many governments in resources-limited settings. Only the study in the US examined the impact of delayed vaccine supplies by a few months [40]. As such, they did not fully assess the trade-off between sub-population groups within the same setting. Furthermore, only the UK study explored the value of NPIs alongside vaccination, it also came to the same conclusion as this study that social distancing practice should be maintained until population-wide vaccine

![Graphs showing expected incremental NMB vs probability of vaccine blocking transmission.](image)

**Notes:** Panel A: 70% efficacy + 1-year protection duration; Panel B: 90% efficacy + 1-year protection duration; Panel C: 50% efficacy + 1-year protection duration; Panel D: 70% efficacy + half-year protection duration. Expected incremental NMB of two vaccination strategies compared to no vaccine was calculated with social distancing being implemented.

**Fig. 5** Expected incremental NMB vs Probability of Vaccine Blocking Transmission
coverage is sufficient to achieve herd immunity [39]. Also, our study and the UK study [39] agree that serious adverse events do not impact the value for money conclusion for vaccines. Unlike other studies, our findings indicate that mandatory state quarantine for PUIs or infected individuals consume significant costs to the Thai society. This is part of the NPIs for which the costs were fully subsidized by the Thai government. In addition, it is uncertain whether differential quarantine and testing policies for vaccinated populations who have had high-risk exposure to COVID-19 patients can be implemented since there is currently a lack of evidence, policies and guidelines [42].

The results of this study must be interpreted with caution. Notably, the mathematical model was matched to the projected data of Thai population’s contact patterns [43] and national COVID-19 outbreak data. Thus, the findings are likely to be primarily applicable to similar settings with limited or low-level community transmission. Specifically, the context and findings were from the mid-2020 period in Thailand which may appear outdated given the COVID-19 situation in Thailand in 2021 and 2022. However, the findings may inform future pandemic and situations in countries that face similar contexts where procurement of vaccines might already take place, but the continuing supply was uncertain. Our economic evaluation was able to give some insights on the affordability of the new strategy (i.e. the “can we do it” question). The results provided justification for the government to secure additional budget from external sources (loan money) in order to procure COVID-19 vaccines (in order to complement or even substitute NPIs). However, our economic evaluation does have little power in explaining the accessibility to implement (the “do we reach those in need” question), or the measurement of the adequacy of the strategy developed (the “monitoring” question); areas where future research can explore further [44–46].

Moreover, the vaccines considered in the analyses were hypothetical, based on the WHO’s TPP characteristics. The results of this study cannot directly correspond to individual vaccines currently available in the global market. We selected this approach because it allows decision-makers assessing the value for money of new vaccines, or existing vaccines as new information becomes available. Although this study adopted a societal perspective, we did not include the productivity loss due to COVID-19 infected patients. This will not alter our findings and conclusion given the small size of people infected in the country. Also, this study considered relatively low costs of social distancing, when compared to the UK study which applied a much higher societal cost for NPIs (1% compared to 2% of GDP) [39]. We also acknowledge that this is a difficult question with no clear-cut answers, as country contexts can change rapidly, and there is also no standard methodology to accurately quantify the economic cost of NPIs. Lastly, there is a lot of individual parameter uncertainty in the model, particularly related to vaccine-related parameters (e.g. vaccine hesitancy), COVID-19 clinical parameters, and economic parameters. These uncertainties should be addressed by evidence generation activities from effective monitoring and evaluation systems. For example, the effectiveness and efficiency of vaccination program will depend significantly on vaccine hesitancy in the population, leading to an important research area on vaccine hesitancy where more details in the Thai context can be found elsewhere [44, 45, 47]. As such, inputs from this study could be used to inform and develop these frameworks for monitoring and evaluation of

\[ \text{Fig. 6 EVPI vs Probability of vaccine blocking infection} \]
COVID-19 vaccination including its short- and long-term impact at national and global levels.

**Conclusion**

COVID-19 vaccines are likely to be cost-saving or cost-effective in resource-limited settings with limited or low-level community transmission. Regarding the target population, the preferred vaccination strategy depended on the type of vaccine efficacy realized. High-incidence groups should be vaccinated if the probability of vaccines blocking infection is high. Elderly groups should be prioritized over high-incidence groups if the only effect of vaccines is to prevent severe infections among COVID-19 cases.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s10198-022-01505-2.

**Author contributions** Conceptualization: YW, NL, WI, JP, CP, YT; methodology: YW, NL, WI, JP, CP, YT; formal analysis and investigation: YW, NL, JRB, YT; writing—original draft preparation: YW, JP, CP, YT; writing—review and editing: YW, NL, WP, WI, JP, SS, CP, JRB, YT; funding acquisition: YT, JP, WI; resources: YT, WP and supervision: YT, WP, WI.

**Funding** Health Systems Research Institute, World Health Organization.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Wouters, O.J., Shadlen, K.C., Salcher-Konrad, M., Pollard, A.J., Larson, H.J., Teerawattananon, Y., et al.: Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. The Lancet 397(10278), 1023–1034 (2021)
2. The McGill University Interdisciplinary Initiative in Infection and Immunity (MI4). COVID-19 vaccine tracker 2021 [cited 2021 May 24]. Available from: https://covid19.trackvaccines.org/
3. Tangcharoensathien, V., Witthayapipopsakul, W., Panichkriangkrai, W., Patcharanarumol, W., Mills, A.: Health systems development in Thailand: a solid platform for successful implementation of universal health coverage. The Lancet 391(10126), 1205–1223 (2018)
4. Tangcharoensathien V, Srithamrongswat S, Pitayarangsarit S. Overview of health insurance systems. Health insurance systems in Thailand, 2002:28–38
5. Reuters. Thailand starts long awaited COVID-19 vaccination drive 2021 [Available from: https://www.reuters.com/world/asia-pacific/thailand-starts-long-awaited-covid-19-vaccination-drive-2021-06-07/]
6. Bank of Thailand. Monetary Policy Report 2017 [cited 2021 May 24]. Available from: https://www.bot.or.th/English/MonetaryPolicy/MonetPolicyCommittee/MPR/BOX_MPR/BOX_MPR_March_2017_3.pdf
7. Luangsanatip N, Pan-Ngum W, Prawjaeng J, Saralamba S, White L, Aguas R, et al. Optimal vaccine strategy to control COVID-19 pandemic in middle-income countries: Modelling case study of Thailand 2021 [Available from: https://www.researchsquare.com/article/rs-270635/v1]
8. Aguas, R., White, L., Hupert, N., Shretta, R., Pan-Ngum, W., Celhay, O., et al.: Modelling the COVID-19 pandemic in context: an international participatory approach. BMJ Glob Health 5(12), e003126 (2020)
9. World Health Organization. WHO Target Product Profiles for COVID-19 Vaccines 2020 [cited 2021 Jun 9]. Available from: https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines
10. Painter, C., Isaranuwatchai, W., Prawjaeng, J., Wee, H. L., Chua, B. W. B., Huyhn, V. A., & Teerawattananon, Y. Avoiding trouble ahead: lessons learned and suggestions for economic evaluations of COVID-19 vaccines. Appl Health Econ Health Policy 19(4), 463–472 (2021)
11. National Health Security Office. Electronic individual records of an e-claim database during 1 March-June 2020 [cited 2020 Jul 31]
12. Department of medical science of Thailand. Reimbursement guideline for diagnostic test and Personal protective equipment (PPE). (2021)
13. Imsanguan, W., Bupachat, S., Wanchaiathanawong, V., Luangjina, S., Thawtheong, S., Nedruwan, S., et al.: Contact tracing for tuberculosis. Thailand 98(3), 212 (2020)
14. He, J., Guo, Y., Mao, R., Zhang, J.: Proportion of asymptomatic coronavirus disease 2019: a systematic review and meta-analysis. J. Med. Virol. 93(2), 820–830 (2021)
15. Thai Department of Disease Control. Corona Virus Disease (COVID-19): Thailand Situation 2021 [cited 2021 Jan 31]. Available from: https://ddc.moph.go.th/viralpneumonia/eng/index.php
16. Shopee. Mask and alcohol gel [cited 2021 Jan 21]. Available from: https://shopee.co.th/
17. Terry M. UPDATED Comparing COVID-19 Vaccines: Timeframes, Types and Prices 2021 [cited 2020 Dec 13]. Available from: https://www.biospace.com/article/comparing-covid-19-vaccines-pfizer-biontech-moderna- astrazeneca-oxford-j-and-j-russia-sputnik-v/
18. Meeyai A, Kotirum S, Praditsithikorn N, Kulpeng W, Cooper BS, Teerawattananon Y. Cost-utility analysis of seasonal influenza vaccine among school children in Thailand 2013 [cited 2021 Jun 9]. Available from: https://www.hitap.net/documents/20324
19. Østergaard, S.D., Schmidt, M., Horváth-Puhó, E., Thomsen, R.W., Sørensen, H.T.: Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence? The Lancet 397(10283), 1441–1443 (2021)
20. National Health Security Office. 2019 Electronic individual records of an e-claim database [cited 2021 May 15]
21. Thai Department of Disease Control. Proposal for state/local quarantine expense. 2021
22. Office of the national economic and social development council. Gross domestic product chain volume measures 1/2021 [cited...
23. The Stock Exchange of Thailand. SETSMART [cited 2021 Jun 9]. Available from: https://www.setsmart.com/ssm/login
24. https://www.sspjournal.org/articles/10.3389/ijph.2022.1604854/full
25. Thai ministry of commerce. Report for consumer price index of Thailand year 2020 base year 2015 [cited 2020 Dec 20]. Available from: http://www.indexpr.moc.go.th/price_present/TableIndexG_region.asp?table_name=cpig_index_country&province_code=5&type_code=g&check_f=i&year_base=2558&nyear=2563
26. World Health Organization. Global health observatory data repository: life tables by country Thailand [cited 2020 Dec 15]. Available from: https://apps.who.int/gho/data/?theme=main&vid=61640
27. Voysey, M., Clemens, S.A.C., Madhi, S.A., Weckx, L.Y., Folegatti, P.M., Aley, P.K., et al.: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269), 99–111 (2021)
28. Doshi, P.: Will covid-19 vaccines save lives? Current trials aren’t designed to tell us. BMJ 371, m4037 (2020)
29. Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M.A., et al.: BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384(15), 1412–1423 (2021)
30. Hall, V.J., Foukles, S., Saei, A., Andrews, N., Ogut, B., Charlett, A., et al.: COVID-19 vaccine coverage in healthcare workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet 397(10286), 1725–1735 (2021)
31. Thompson, M.G., Burgess, J.L., Nalwanyo, E.L., Tyner, H.L., Yoon, S.K., Meece, J., et al.: Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - eight US locations, December 2020–March 2021. MMWR Morb. Mortal Wkly. Rep. 70(13), 495–500 (2021)
32. Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., et al.: COVID-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532–1546 (2022)
33. Hayawi, K., Shabriar, S., Serhani, M.A., Alashwal, H., Masud, M.M.: Vaccine versus Variants (3Vs): are the COVID-19 vaccines effective against the variants? A systematic review. Vaccines 9(11), 1305 (2021)
34. Teerawattananon, Y., Sarin, K., Chi, Y.-L., Dabak, S., Kazibwe, J., Clapham, H., et al.: Recalibrating the notion of modelling for policymaking during pandemics. Epidemics 38, 100552 (2022)
35. Wanrudee Isaranuwatchai, Juthamas Prawjaeng. One year after COVID-19, how will we live with them? In: The 101, editor. https://www.the101.world/wanrudee-and-juthamas-hitap-interview/2021
36. Penluck Pakdeecharoen. Once COVID-19 vaccines arrive, how to choose? Bangkok Business. 2021
37. Yot Teerawattananon, Juthamas Prawjaeng. COVID-19 vaccines, who should be vaccinated first and why? In: HITAP, editor. https://www.hitap.net/documents/1800752020
38. Spychalski, P., Blażyńska-Spychalska, A., Kobiela, J.: Estimating case fatality rates of COVID-19. Lancet Infect. Dis. 20(7), 774–775 (2020)
39. Sandmann, F.G., Davies, N.G., Vassall, A., Edmunds, W.J., Jit, M.: The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. Lancet Infect. Dis. (2021). https://doi.org/10.1016/S1473-3099(21)00079-7
40. Kohli, M., Maschio, M., Becker, D., Weinstein, M.C.: The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine. 39(7), 1157–1164 (2021)
41. Hagens, A., Inkaya, A., Yüldirak, K., Sancar, M., van der Schans, J., Acar Sancar, A., et al.: COVID-19 vaccination scenarios: a cost-effectiveness analysis for Turkey. Vaccines. 9(4), 399 (2021)
42. Kc, S., Ananthakrishnan, A., Painter, C., Butani, D., Teerawattananon, Y.: Research collaboration is needed to inform quarantine policies for health-care workers. Lancet. 397(10292), 2334 (2021). https://doi.org/10.1016/S0140-6736(21)01224-1
43. Prem, K., Cook, A.R., Jit, M.: Projecting social contact matrices in 152 countries using contact surveys and demographic data. PLoS Comput. Biol. 13(9), e1005697 (2017)
44. Pheerapanyawaranun, C., Wang, Y., Siddiqui, N., Srisarn, K., Teerawattananon, Y., Isaranuwatchai, W.: COVID-19 vaccine hesitancy among health care workers in Thailand: The comparative results of two cross-sectional online surveys before and after vaccine availability. Front Public Health 10, 834545 (2022). https://doi.org/10.3389/fpubh.2022.834545
45. Nachawich Kittidovorndit, Chatkamol Pheerapanyawaran, Voices of foreign migrant workers and their COVID-19 vaccine need. In: HITAP, editor. https://www.hitap.net/documents/1812322021
46. Teerawattananon, Y., Anothaisintawee, T., Pheerapanyawaran, C., Botwright, S., Akksilp, K., Sirichumroonwit, N., et al.: A systematic review of methodological approaches for evaluating real-world effectiveness of COVID-19 vaccines: advising resource-constrained settings. PLoS ONE 17(1), e0261930 (2022)
47. Nopphadol Pimsarn, Chatkamol Pheerapanyawaran, Thamconwan Dulsamphan, Nicha Moonkham, Peeraphol Kanjanakan. What to do when healthcare workers did not get COVID-19 second dose? In: HITAP, editor. https://www.hitap.net/documents/1811222021

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.